ROCKWELL MEDICAL INC
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. - Other Information
Director and executive officer trading arrangements
The following table provides information concerning Rule 10b5-1 trading arrangements adopted during the three months ended June 30, 2024, by any director or any executive officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934. These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). No non-Rule 10b5-1 trading arrangements were adopted by any director or executive officer during the second quarter of 2024. In addition, no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were terminated by any director or executive officer in the second quarter of 2024.
| Name | Title | Adoption Date | Duration(a) | Number of shares to be sold |
|---|---|---|---|---|
| Mark Strobeck | President and CEO | May 31, 2024 | May 31, 2024 – October 2, 2025 | 25,104 |
| Timothy Chole | SVP and Chief Commercial Officer | June 7, 2024 | June 7, 2024 – October 2, 2025 | 10,606 |
a Subject to compliance with Rule 10b5-1, duration could cease earlier than the final date shown above to the extent that the aggregate number of shares to be sold under the trading arrangement have been sold.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.